Prototype development for Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination

Open Solicitation Posted

Solicitation number
HT9427-26-R-E020
Agency
Not on record
Responses due
Set-aside
No set-aside

Opportunity facts

Place of performance
Frederick, Maryland, United States

Notice details come from SAM.gov. Updated .

About this opportunity

The Defense Health Agency Contracting Activity (DHACA) seeks prototype development of a Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination product through one award under prototype Other Transaction Authority (10 U.S.C. 4022), with proposals due November 20, 2026 at 12:00 PM Eastern. DHACA is procuring on behalf of the Warfighter Protection and Acute Care Project Management Office (WPAC PMO) within the Defense Health Agency's Portfolio Acquisition Executive for Medical Products. No set-aside is used. Offerors must satisfy at least one statutory condition: (A) a nontraditional defense contractor or nonprofit research institution participates to a significant extent, (B) all significant participants other than the Government are small businesses or nontraditional defense contractors, or (C) at least one-third of total project cost is paid by non-Federal parties.

The product must be a combination wound treatment with a barrier component infused or impregnated with antimicrobial and/or antifungal properties, and it must achieve FDA approval or clearance. The performer must serve as FDA Sponsor under 21 C.F.R. 312 Subpart D and reach TRL 7 at FDA submission and TRL 8 upon approval. Required attributes include a minimum 12-month shelf life, barrier integrity for at least 24 hours, and antimicrobial efficacy against bacteria at minimum. Deliverables include 250 prototype units with instructions for use. Offerors must submit a CMMC Level 1 self-assessment.

Place of performance is listed as Frederick, Maryland. The Statement of Objectives (Amendment 0004) permits studies domestically or internationally under FDA standards and allows manufacturing worldwide, subject to FDA facility compliance.

The estimated period of performance is 54 months: Objective 1 (24 months), Objective 2 (24 months), and Objective 3 (6 months for FDA review). Objectives 1 and 2 may overlap but cannot exceed 48 months combined. The Government prefers a Firm Fixed Price pOTA and will accept Cost-Plus Fixed Fee. Funding is incremental, with a schedule provided at award.

The Government will select the proposal demonstrating the greatest likelihood of successfully developing and delivering the prototype. Proposals comprise three volumes: Volume I (technical approach, 20-page limit, plus unlimited Statement of Work), Volume II (management approach, 20-page limit), and Volume III (administrative and cost/price, including FDA Form 1571 and warranties and representations). Offerors must disclose concurrent proposals or awards for similar work and any prior SBIR work. Offerors register in SAM.gov under NAICS 541715.

Amendment 0005 (November 13, 2026) is the current RPP. Amendment 0004 (November 12, 2026) updated the Statement of Objectives, draft agreement terms, and SOW template, and added Attachment K. Amendments 0002 and 0003 moved the proposal due date from October 23 to November 20, 2026.

Notice text

6 versions

Update #6 · Latest ·

This RPP is being issued by the Defense Health Agency Contracting Activity (DHACA), in support of the Defense Health Agency’s Portfolio Acquisition Executive (PAE) Medical Products (MP) Warfighter Protection (WPAC) & Acute Care Program Management Office (PMO) Care located in Frederick, Maryland at Fort Detrick. The Warfighter Protection and Acute Care Project Management Office (WPAC PMO) has a requirement for the development of a Barrier Combination product. The Barrier Combination product is defined as being composed of both a physical barrier to protect a wound and an antibacterial and/or antifungal activity released from the barrier to prevent the spread of organisms and avoid systemic infections.


This RPP will result in one award to develop the Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination (BC) prototype product.


The final product MUST be a combination wound treatment that includes a barrier component that is either infused or impregnated with antimicrobial and/or antifungal properties and have U.S. Food Drug Administration (FDA) approval (or clearance).


The award, as a result of this RPP, will be awarded under the authority of prototype Other Transaction Authority (pOTA) 10 U.S.C. 4022.

NOTE: Another amendment will be posted which will include Offeror questions and Government responses. (Amendment 0003 only extends the proposal due date).

Amendment 0001 – removed alternate point of contact information under “Contract Information” on SAM.gov
Amendment 0002 – revised proposal due date from: 12:00pm eastern, Friday, 23 Oct 2026  to: 12:00pm eastern Friday, 06 Nov 2026
Amendment 0003 – revised proposal due date from: 12:00pm eastern Friday, 06 Nov 2026 to: 12:00pm eastern Friday, 20  Nov 2026

Amendment 0004 – Incorporates Attachment J - Offeror questions & Government responses, Updates RPP, Attachment A – SOO, Attachment E- Draft Agreement Terms & Conditions, Attachment H – SOW Template, and adds Attachment K – CMMC Level I Self-Assessment Instructions.

Amendment 0005 - Incorporates updates to RPP.

Update #5 ·

This RPP is being issued by the Defense Health Agency Contracting Activity (DHACA), in support of the Defense Health Agency’s Portfolio Acquisition Executive (PAE) Medical Products (MP) Warfighter Protection (WPAC) & Acute Care Program Management Office (PMO) Care located in Frederick, Maryland at Fort Detrick. The Warfighter Protection and Acute Care Project Management Office (WPAC PMO) has a requirement for the development of a Barrier Combination product. The Barrier Combination product is defined as being composed of both a physical barrier to protect a wound and an antibacterial and/or antifungal activity released from the barrier to prevent the spread of organisms and avoid systemic infections.


This RPP will result in one award to develop the Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination (BC) prototype product.


The final product MUST be a combination wound treatment that includes a barrier component that is either infused or impregnated with antimicrobial and/or antifungal properties and have U.S. Food Drug Administration (FDA) approval (or clearance).


The award, as a result of this RPP, will be awarded under the authority of prototype Other Transaction Authority (pOTA) 10 U.S.C. 4022.

NOTE: Another amendment will be posted which will include Offeror questions and Government responses. (Amendment 0003 only extends the proposal due date).

Amendment 0001 – removed alternate point of contact information under “Contract Information” on SAM.gov
Amendment 0002 – revised proposal due date from: 12:00pm eastern, Friday, 23 Oct 2026  to: 12:00pm eastern Friday, 06 Nov 2026
Amendment 0003 – revised proposal due date from: 12:00pm eastern Friday, 06 Nov 2026 to: 12:00pm eastern Friday, 20  Nov 2026

Amendment 0004 – Incorporates Attachment J - Offeror questions & Government responses, Updates RPP, Attachment A – SOO, Attachment E- Draft Agreement Terms & Conditions, Attachment H – SOW Template, and adds Attachment K – CMMC Level I Self-Assessment Instructions.

Update #4 ·

This RPP is being issued by the Defense Health Agency Contracting Activity (DHACA), in support of the Defense Health Agency’s Portfolio Acquisition Executive (PAE) Medical Products (MP) Warfighter Protection (WPAC) & Acute Care Program Management Office (PMO) Care located in Frederick, Maryland at Fort Detrick. The Warfighter Protection and Acute Care Project Management Office (WPAC PMO) has a requirement for the development of a Barrier Combination product. The Barrier Combination product is defined as being composed of both a physical barrier to protect a wound and an antibacterial and/or antifungal activity released from the barrier to prevent the spread of organisms and avoid systemic infections.


This RPP will result in one award to develop the Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination (BC) prototype product.


The final product MUST be a combination wound treatment that includes a barrier component that is either infused or impregnated with antimicrobial and/or antifungal properties and have U.S. Food Drug Administration (FDA) approval (or clearance).


The award, as a result of this RPP, will be awarded under the authority of prototype Other Transaction Authority (pOTA) 10 U.S.C. 4022.

NOTE: Another amendment will be posted which will include Offeror questions and Government responses. (Amendment 0003 only extends the proposal due date).

Amendment 0001 – removed alternate point of contact information under “Contract Information” on SAM.gov
Amendment 0002 – revised proposal due date from: 12:00pm eastern, Friday, 23 Oct 2026  to: 12:00pm eastern Friday, 06 Nov 2026
Amendment 0003 – revised proposal due date from: 12:00pm eastern Friday, 06 Nov 2026 to: 12:00pm eastern Friday, 20  Nov 2026

Update #3 ·

This RPP is being issued by the Defense Health Agency Contracting Activity (DHACA), in support of the Defense Health Agency’s Portfolio Acquisition Executive (PAE) Medical Products (MP) Warfighter Protection (WPAC) & Acute Care Program Management Office (PMO) Care located in Frederick, Maryland at Fort Detrick. The Warfighter Protection and Acute Care Project Management Office (WPAC PMO) has a requirement for the development of a Barrier Combination product. The Barrier Combination product is defined as being composed of both a physical barrier to protect a wound and an antibacterial and/or antifungal activity released from the barrier to prevent the spread of organisms and avoid systemic infections.


This RPP will result in one award to develop the Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination (BC) prototype product.


The final product MUST be a combination wound treatment that includes a barrier component that is either infused or impregnated with antimicrobial and/or antifungal properties and have U.S. Food Drug Administration (FDA) approval (or clearance).


The award, as a result of this RPP, will be awarded under the authority of prototype Other Transaction Authority (pOTA) 10 U.S.C. 4022.

NOTE: Another amendment will be posted which will include Offeror questions and Government responses. (Amendment 0003 only extends the proposal due date).

Update #2 ·

This RPP is being issued by the Defense Health Agency Contracting Activity (DHACA), in support of the Defense Health Agency’s Portfolio Acquisition Executive (PAE) Medical Products (MP) Warfighter Protection (WPAC) & Acute Care Program Management Office (PMO) Care located in Frederick, Maryland at Fort Detrick. The Warfighter Protection and Acute Care Project Management Office (WPAC PMO) has a requirement for the development of a Barrier Combination product. The Barrier Combination product is defined as being composed of both a physical barrier to protect a wound and an antibacterial and/or antifungal activity released from the barrier to prevent the spread of organisms and avoid systemic infections.


This RPP will result in one award to develop the Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination (BC) prototype product.


The final product MUST be a combination wound treatment that includes a barrier component that is either infused or impregnated with antimicrobial and/or antifungal properties and have U.S. Food Drug Administration (FDA) approval (or clearance).


The award, as a result of this RPP, will be awarded under the authority of prototype Other Transaction Authority (pOTA) 10 U.S.C. 4022.

NOTE: Another amendment will be posted which will include Offeror questions and Government responses. (Amendment 0002 only extends the proposal due date).

Update #1 ·

This RPP is being issued by the Defense Health Agency Contracting Activity (DHACA), in support of the Defense Health Agency’s Portfolio Acquisition Executive (PAE) Medical Products (MP) Warfighter Protection (WPAC) & Acute Care Program Management Office (PMO) Care located in Frederick, Maryland at Fort Detrick. The Warfighter Protection and Acute Care Project Management Office (WPAC PMO) has a requirement for the development of a Barrier Combination product. The Barrier Combination product is defined as being composed of both a physical barrier to protect a wound and an antibacterial and/or antifungal activity released from the barrier to prevent the spread of organisms and avoid systemic infections.


This RPP will result in one award to develop the Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination (BC) prototype product.


The final product MUST be a combination wound treatment that includes a barrier component that is either infused or impregnated with antimicrobial and/or antifungal properties and have U.S. Food Drug Administration (FDA) approval (or clearance).


The award, as a result of this RPP, will be awarded under the authority of prototype Other Transaction Authority (pOTA) 10 U.S.C. 4022.

Files

File Type Posted
RPP for BWI-PT-Barrier (pOTA) - Amendment 0005.pdf PDF
B08 -Attachment K - CMMC Level 1 self-assessment instructions (INFORMATION ONLY).pdf PDF
B08-Attachment A-SOO-Amendment 0004.pdf PDF
B08-Attachment E-Draft Agreement Terms Conditions-Amendment 0004.pdf PDF
B08-Attachment J - Govt Responses - Amendment 0004.xlsx XLSX spreadsheet
B08-RPP for BWI-PT-Barrier (pOTA) - Amendment 0004.pdf PDF
B08-Attachment H-SOW-Amendment 0004.pdf PDF
B08-HT9427-26-R-E020-Amendment 0003-RPP for BWI-PT-Barrier (pOTA).pdf PDF
HT9427-26-R-E020-Amendment 0002-RPP for BWI-PT-Barrier (pOTA).pdf PDF
Attachment A - Statement of Objectives (SOO).pdf PDF
Attachment D1 - FDA Form 1571.pdf PDF
Attachment E - Draft Agreement Terms and Conditions.pdf PDF
Attachment F - Warranties and Representatives.docx DOCX document
Attachment H - Statement of Work Template (see Section 11).docx DOCX document
HT9427-26-R-E020-RPP for BWI-PT-Barrier (pOTA).pdf PDF
Attachment B - Contract Data Requirements List (CDRL).pdf PDF
Attachment C - Data Item Description (DID) DI-TCSP-82040 (REFERENCE ONLY).pdf PDF
Attachment D2 - FDA Form 1571 Instructions (REFERENCE ONLY).pdf PDF
Attachment G1 - Cost Sheet Template.xlsx XLSX spreadsheet
Attachment G2 - Firm Fixed Price Sheet Template.xlsx XLSX spreadsheet
Attachment I1 - Technology Readiness Level (TRL) for drug and biologics (REFERENCE ONLY).pdf PDF
Attachment I2-Technology Readiness Level (TRL) for diagnostics and devices (REFERENCE ONLY).pdf PDF
Attachment J - Offeror question form.xlsx XLSX spreadsheet
Show all 23

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity

GovTribe for Federal Contractors